Role of Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer Patients: A Study from the Japanese Breast Cancer Registry
The role of postmastectomy radiotherapy (PMRT) in breast cancer patients receiving neoadjuvant chemotherapy (NAC) is controversial. We aimed to evaluate the effectiveness of radiotherapy in patients treated with NAC and mastectomy in the Japanese Breast Cancer Registry.
We enrolled patients who received NAC and mastectomy for cT1–4 cN0–2 M0 breast cancer. We evaluated the association between radiotherapy and outcomes, locoregional recurrence (LRR), distant disease-free survival (DDFS), and overall survival (OS) based on ypN status by multivariable analysis.
Of the 145,530 patients, we identified 3226 who met the inclusion criteria. Among ypN1 patients, no differences were found in LRR, DDFS, or OS between groups with and without radiotherapy (p = 0.72, p = 0.29, and p = 0.36, respectively). Radiotherapy was associated with improved LRR-free survival (p < 0.001), DDFS (p = 0.01), and OS (p < 0.001) in patients with ypN2–3. Multivariable analysis demonstrated that use of radiotherapy was independently associated with improved LRR [hazard ratio (HR) 0.61, 95% confidence interval (CI) 0.45–0.82, p = 0.001] and OS [HR 0.69, 95% CI 0.53–0.89, p = 0.004) for ypN2–3 patients only. The association between radiotherapy and OS was not statistically significant among ypN0 (p = 0.22) and ypN1 patients (p = 0.51).
The results from this nationwide database study did not show significant associations between PMRT and improved survival among ypN0 and ypN1 patients. Radiotherapy may be beneficial only for ypN2–3 breast cancer patients who receive NAC and mastectomy in the modern era.
We thank the JBCS for their grant support to perform the present study. We also thank the affiliated institutes participating in the Japanese Breast Cancer Registry of the JBCS for their efforts to register patients’ data.
Drs. Kumamaru and Miyata are affiliated with the department of Healthcare Quality Assessment at the University of Tokyo, which is a social collaboration department supported by National Clinical Database, Johnson & Johnson KK., and Nipro corporation. The other authors declare no conflicts of interest.
- 7.Liu J, Mao K, Jiang S, et al. The role of postmastectomy radiotherapy in clinically node-positive, stage II–III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB. Oncotarget 2016; 7: 24848–59.Google Scholar
- 11.Kurebayashi J, Miyoshi Y, Ishikawa T, et al. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: based on the breast cancer registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer 2015; 22: 235–44.CrossRefGoogle Scholar
- 14.Japanese Breast Cancer Society Guidelines 2018. Available: http://jbcs.gr.jp/guidline/2018/. Accessed 31 Jan 2019.
- 15.National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology, breast cancer. Version 3, 2018. Available: http://www.nccn.org/professionals/physician_gls/default.aspx#site. Accessed 31 Jan 2019.